MDM2 and cancer: Considering that CCDC106 competes with Mdm2/MdmX for binding p53 identified in this work, we reason that the CCDC106-p53 interaction should be a promising drug target for cancer killing in synergetic combination with drugs targeting aberrant p53-Mdm2/MdmX interactions.